AstraZeneca sees study fuelling Crestor sales
LONDON (Reuters) - A study showing Crestor reduces the risk of death and heart problems in some patients with low or normal cholesterol will be key to the future sales of the medicine, its maker AstraZeneca Plc said on Tuesday.
<p><img src="http://feeds.reuters.com/~a/reuters/businessNews?i=Ho4Xoq" border="0"></img> (http://feeds.reuters.com/~a/reuters/businessNews?a=Ho4Xoq)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/businessNews?i=AwHyWzG" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=AwHyWzG) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=BT7LbIg" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=BT7LbIg) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=zU6TPog" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=zU6TPog)
</div><img src="http://feeds.reuters.com/~r/reuters/businessNews/~4/261929089" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/261929089/idUSL0174532120080401